Publication: Paclitaxel and Carboplatin in Combination in the Treatment of Advanced Non-small-cell Lung Cancer (NSCLC) : A Preliminary Study
Issued Date
1998-10-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0031740908
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.81, No.10 (1998), 762-771
Suggested Citation
Vorachai Ratanatharathorn, Manmana Jirajarus, Ekaphop Sirachainan, Suwannee Sirilerttrakul, Anuparp Euaree, Pornchulee Supatchaipisit Paclitaxel and Carboplatin in Combination in the Treatment of Advanced Non-small-cell Lung Cancer (NSCLC) : A Preliminary Study. Journal of the Medical Association of Thailand. Vol.81, No.10 (1998), 762-771. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/18467
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Paclitaxel and Carboplatin in Combination in the Treatment of Advanced Non-small-cell Lung Cancer (NSCLC) : A Preliminary Study
Other Contributor(s)
Abstract
This study was aimed to determine the activity and toxicity of combination paclitaxel and carboplatin in stage III B and IV NSCLC. Eligibililty required performance status. Paclitaxel was administered at a dose of 200 mg/m2, 3-hour infusion, followed by carboplatin at a tartgeted area under the concentration-time curve (AUC) of 6. Treatment was repeated at 3-week intervals for 6 courses. G-CSF 5 microgram/kg was subcutaneously injected during subsequent courses if there was grade 3-4 leukopenia or granulocytopenia in the previous course. From August 1996 through June 1997, 15 patients were enrolled. The median age was 47 years (range 20-68 years), 60 per cent were female. 73.3 per cent had adenocarcinoma, and 66.7 per cent had stage III B disease. Eighty three courses were administered; 13 patients (86.7%) completed all six cycles. The objective response rate was 53.3 per cent, with 1 (6.7%) complete response and 7 (46.7%) partial responses. Pleural effusion, lung lesion and lymph node were the three most common sites that responded to chemotherapy. The major toxicity was myelosuppression. Grade 3 or 4 granulocytopenia, anemia and thrombocytopenia were observed in 18 per cent, 7.2 per cent and 1.2 per cent, respectively, of 83 courses administered. Four episodes of febrile neutropenia (4.8%) occurred in 3 patients. There was one episode of anaphylaxis during Paclitaxel infusion. Other common toxicities were mild myalgia, paresthesias, alopecia and fatigue. Most of the toxicities showed cumulative effect. Paclitaxel plus carboplatin is a moderately active regimen in advanced NSCLC. Toxicities of this regimen are well tolerated.